Hematopoietic Stem Cell Transplantation in ARPC1B Deficiency

Stefano Giardino*, Stefano Volpi, Federica Lucioni, Roberta Caorsi, Jennifer Schneiderman, Abigail Lang, Amer Khojah, Taco Kuijpers, Ionanna Papadatou, Anna Paisiou, Laura Alonso, Ansgar Schulz, Nufar Marcus, Marco Gattorno, Maura Faraci

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Mutations in the ARPC1B isoform component of human actin-related protein 2/3 complex have been recently associated with an inborn error of immunity characterized by combined immunodeficiency, allergies, autoinflammation, and platelet abnormalities. Currently, indications on the management of this novel disease and information on its outcome are lacking. We report the first case series of 7 children with a homozygous mutation in ARPC1B gene who underwent allogeneic-HSCT (allo-HSCT). All patients presented an early clinical onset, characterized by recurrent infections, failure to thrive and gastrointestinal bleeding episodes complicated with neonatal hemorrhagic enteritis in 3 cases, and macrophage activating syndrome in 2. Allo-HSCT was performed at the median age of 1.83 years after a myeloablative conditioning regimen in all cases. Engraftment occurred in all patients with full donor chimerism in 6 out of 7. The clinical course after engraftment was uneventful in 3 out of 7 children; 2 patients developed a grade 1–2 acute graft-versus-host disease (GvHD), and 1 patient a grade 1 chronic-GvHD. JC virus-related progressive multifocal leukoencephalopathy was diagnosed in one patient 13 months after haploidentical-HSCT and successfully managed with donor-derived viral-specific T-cell infusion. Only one patient had a fatal outcome 3 months after HSCT because of sepsis, after veno-occlusive disease, and transplant-associated microangiopathy. At a median follow-up of 19 months (range 3–110), 6 out of 7 patients are alive and disease-free. The severity of the clinical phenotype at diagnosis and the high survival rate, with limited transplant-related morbidity, strongly support the indication to allo-HSCT for patients with this diagnosis.

Original languageEnglish (US)
Pages (from-to)1535-1544
Number of pages10
JournalJournal of Clinical Immunology
Issue number7
StatePublished - Oct 2022


  • ARPC1B deficiency
  • Allogenic-HSCT
  • Autoinflammatory disease
  • Primary immunodeficiency

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Hematopoietic Stem Cell Transplantation in ARPC1B Deficiency'. Together they form a unique fingerprint.

Cite this